

ASGO 2019

The 6th Biennial Meeting of Asian Society of Gynecologic Oncology

Date: October 10th-12th, 2019

Venue: Songdo Convensia,
Incheon, Korea

**“Optimal Gynecologic
Cancer Care in Asia”**

PROGRAM BOOK

Hosted by



Supported by





ASGO 2020

6th International Workshop on Gynecologic Oncology

Date | May 2-3, 2020

Venue | Taipei Nangang Exhibition Center, Hall 2

Organized by TAGO

President of ASGO

Prof. Hee-Sug Ryu
Ajou University

Organizing Committee Chairperson

Prof. Chih-Ming Ho
President of TAGO



ASGO 2019

The 6th Biennial Meeting of
Asian Society of Gynecologic Oncology

C O N T E N T S	
Welcome Message	02
Organization of ASGO	03
Organizing Committee of ASGO 2019	04
ASGO 2019 Information	06
Speaker Information	08
Poster Presentation (Display) Schedule	09
Become a Member of ASGO	10
Program at a Glance	11
Scientific Program	15
Thursday, October 10	
Friday, October 11	
Saturday, October 12	
Poster	45
Poster Discussion	
Poster Display	
Tour Information	72
Exhibition	74
Floor plan	76

Secretariat of ASGO Workshop 2020

Rm. 12043, 12F., No. 92, Sec. 2, Zhongshan N. Rd., Zhongshan Dist., Taipei City 104,
Taiwan (R.O.C.) Mackay Memorial Hospital
Tel: +886-2-2511-0730 | E-mail: tago.gyn@gmail.com

Welcome Message

Dear Colleagues and Friends,

Welcome to the 6th Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO 2019) in Korea!

On behalf of the Organizing Committee, we cordially invite you to ASGO 2019 in Songdo, Incheon, Korea from October 10 to 12.

Since 2008, when ASGO was officially founded by a group of gynecologic oncologists in Asia, ASGO has rapidly grown up through hosting five successful biennial meetings and workshops both in Korea and Japan. For the last 11 years, ASGO have made utmost effort to share various studies, educational environment and to promote women's health. Indeed, the Organizing Committee of ASGO 2019 has prepared for the wide range of scientific programs and pleasant social activity programs as well. The 6th Biennial Meeting is expected to be the center of cutting-edge research and education on Gynecologic Oncology as well as hope for gynecologic cancer patients in Asia.

We believe all participants will truly enjoy their time and have an unforgettable memory in ASGO 2019. Extending a warm welcome to all of you here, we really look forward to meeting you at the 6th Biennial Meeting of ASGO.

Sincerely yours,



Hee-Sug Ryu

Hee-Sug Ryu, M.D., Ph.D.

ASGO
President



Seung Cheol Kim

Seung Cheol Kim, M.D., Ph.D.

ASGO 2019
Organizing Committee Chair

Organization of ASGO

[President]	Hee-Sug Ryu (Korea)
[Secretary General]	Suk-Joon Chang (Korea)
[Treasurer]	Jae-Weon Kim (Korea)
[JGO Editor-in-Chief]	Jae-Weon Kim (Korea)
[President-Elect]	Daisuke Aoki (Japan)
[Immediate Past President]	Ikuo Konishi (Japan)
[Nominating Committee]	Shingo Fujii (Japan) Soon-Beom Kang (Korea) Toshiharu Kamura (Japan) Joo-Hyun Nam (Korea)
[Council Members]	Andri Andrijono (Indonesia) Duk-Soo Bae (Korea) Chunling Chen (China) Neerja Bhatla (India) Efrén Domingo (Philippines) Seung Cheol Kim (Korea) Suresh Kumarasamy (Malaysia) Hextan Ngan (Hong Kong) David Tan (Singapore) Nobuo Yaegashi (Japan) Kung-Liahng Wang (Taiwan) Sarikapan Wilailak (Thailand) Rongyu Zang (China)

Organizing Committee of ASGO 2019

[President of ASGO]

Hee-Sug Ryu (Ajou University)

[Chair]

Seung Cheol Kim (Ewha Womans University)

[Secretary General]

Dong Hoon Suh (Seoul National University)

[Advisors]

Soon-Beom Kang (Seoul National University)

Joo-Hyun Nam (University of Ulsan)

Duk-Soo Bae (Sungkyunkwan University)

Young Tak Kim (University of Ulsan)

[Scientific Program Committee]

Chair Jae-Weon Kim (Seoul National University)

Vice Chair Jong Min Lee (Kyung Hee University)

Vice Chair Rongyu Zang (Fudan University)

[Finance Committee]

Chair Yong Man Kim (University of Ulsan)

Vice Chair Tae Jin Kim (Dankook University)

Vice Chair Seok Ju Seong (CHA University)

[International Relations Committee]

Chair Young Tae Kim (Yonsei University)

Vice Chair Sang Young Ryu (Korea Cancer Center)

Vice Chair Chulmin Lee (Inje University)

[Planning Committee]

Chair Soo Young Hur (Catholic University)

Vice Chair Joong Sub Choi (Hanyang University)

Vice Chair Sung Yob Kim (Jeju National University)

[Social Program Committee]

Chair Jae-Kwan Lee (Korea University)

Vice Chair Young-Han Park (Hallym University)

Vice Chair Won Deok Joo (CHA University)

[Advertising Committee]

Chair Yoon Soon Lee (Kyungpook National University)

Vice Chair Ki Hyung Kim (Pusan National University)

Vice Chair Kwang Beom Lee (Gacheon University)

[Exhibition Committee]

Chair Seok Mo Kim (Chonnam National University)

Vice Chair Seob Jeon (Soonchunhyang University)

Vice Chair Seung-Su Han (Chung-Ang University)

[Publication Committee]

Chair Byoung-Gie Kim (Sungkyunkwan University)

Vice Chair Ju-won Roh (Dongguk University)

Vice Chair Sokbom Kang (National Cancer Center)



ASGO 2019 Information

Meeting Venue

Songdo Convensia, Incheon, Korea

- Address: 123 Central Street, Yeonsu-gu, Incheon 21998 Korea

- TEL: +82-32-210-1114 / Website: <http://www.songdoconvensia.com>

Registration

- Place: Lobby (2F), Songdo Convensia

- Registration Desk Opening Hours:

Thursday, October 10	07:30 – 18:30
Friday, October 11	07:30 – 18:30
Saturday, October 12	07:30 – 15:00

- Registration Fee:

Category	On-Site Registration (2019. 10. 10 – 10. 12)
Gynecology Oncologists, Other Department Physician Staffs of the Pharmaceutical Company	500USD
Fellow/ Trainee	400USD
Nurse [ONLY 10.10]	50USD
Nurse / Researcher / Graduate Student / Student	300USD
Accompanying Person [Banquet only (10.10/ 10.11)]	100USD
Accompanying Person [Tour (10.10) + Banquet (10.10/ 10.11)]	300USD

Mobile APP

Install the ASGO 2019 interactive mobile App to your mobile phones and tablets to access all the meeting information.

- Session overview, speakers and exhibitors

- Browse abstracts and presentation files

- Create your personal schedule for the event, including bookmarking the sessions you are interested in

Download the ASGO 2019 App now to enhance your meeting experience! (available on the App Store or Google Play).



Preview Room

All speakers are requested to visit the Preview Room (Room 208) to check your presentation file at least 3 hours before your session starts to ensure your file appears properly.

- Place: Room 208 (2F), Songdo Convensia

- Preview Room Opening Hours:

Thursday, October 10	07:00 – 18:30
Friday, October 11	07:00 – 18:30
Saturday, October 12	07:00 – 15:00

Certificate of Attendance

The certificate of attendance is enclosed in the advertisement book. You can find it at the end of the advertisement book.

WIFI

Free WIFI will be available in selected meeting area, including the exhibition area and the session hall.

- User name: convensia

- Password: asgo2019

Exhibition

- Place: Grand Ballroom C, Lobby (2F), Songdo Convensia

- Exhibition Opening Hours:

Thursday, October 10	09:00 – 18:00
Friday, October 11	09:00 – 18:00
Saturday, October 12	09:00 – 18:00

Smoking Policy

The ASGO 2019 and the concomitant Exhibition have been designated as no-smoking events throughout the entire venue, including all meeting halls, functions, registration and catering areas. All the participants are kindly required to respect the no-smoking policy.

Speaker Information

Speaker Information

- Preview Room Opening Hours:

Thursday, October 10	07:00 – 18:30
Friday, October 11	07:00 – 18:30
Saturday, October 12	07:00 – 15:00

All speakers and oral abstract presenters should deliver and check their presentation files at the Preview Room (Room 208) at least 3 hours before the start of the session. Speakers are kindly required to finish their presentation within the given time limits, including Q&A time.

Chairperson

If you are a chairperson, please be in your session rooms 10 minutes prior to start of the session. For organizational purposes, chairpersons must keep strictly to the time allocated in the program.

Poster Presentation (Display) Schedule

Poster Presentation (Display) Schedule

Set up	Thursday, October 10	09:00 - 18:00
Display	Thursday, October 10	09:00 - 18:00
	Friday, October 11	09:00 - 18:00
	Saturday, October 12	09:00 - 14:00
Removal	Saturday, October 12	14:00 - 15:30

Poster Board Number

Please refer to the page 46 and mobile App to locate your presentation Number. Kindly use this presentation Number only.

Poster Overview

We invite all ASGO 2019 attendees to view posters during the breaks as indicated in the Scientific Program. Poster Viewing Presentations have no specific presentation time. The presenters may stand by the Poster in order to present their Poster during breaks.

Removal

You may remove your poster on Saturday, October 12, from 14:00 to 15:30. Meeting staff will remove all posters left on the boards on Saturday, October 12 at 15:30. Please note that the organizers do not take any responsibility for returning uncollected material to the authors.

Become a Member of ASGO

The Asian Society of Gynecologic Oncology (ASGO) is the leading Asian organization with professionals from over 10 countries involved in prevention, treatment, care and research of gynecologic cancers.

ASGO membership provides the unique opportunity to access to precious resources from previous meetings, establish personal and professional relationships, and participate in all ASGO meetings with discounted registration fee.

Benefits



Access to members-only page

You can find ASGO meeting resources such as abstracts, posters, and congress videos.



Discounted registration fee for all ASGO meetings

Enjoy reduced registration fees to get opportunity to communicate with professionals in our meetings.



Right to participation in vote

You will have right to submit nominations and vote for ASGO officers and council members, and be elected and serve on ASGO committees as well.



VISIT www.asiansgo.org
to become a member of the ASGO!

Program at a Glance

Thursday, October 10

	Thursday, October 10							
	GBR A	GBR B	204-205	206-207	GBR C & Lobby			
08:30	25 th Annual Symposium of KSGO 2019	25 th Annual Symposium of KSGO 2019 [Nursing Session]	Shingo Fujii Medical Academy	29 th KGOG Symposium & 13 th Korea-Japan Gynecologic Oncology Group Joint Meeting	Exhibition & Poster Display			
09:00								
09:30								
10:00								
10:30								
11:00								
11:30								
12:00								
12:30						Break 12:15-12:35	Break	(*Satellite Symposium - Roche Korea)
13:00						Special Symposium 1 Sponsored by AstraZeneca Luncheon 12:35-13:25	12:30-13:45	
13:30	Opening Ceremony 13:25-13:45							
14:00	Plenary 1 President Invited Lectures 13:45-14:45	Shingo Fujii Medical Academy 13:45-14:55						
14:30	Break 14:45-15:05							
15:00	Sympo 1 Rare Gynecologic Cancers: What is new? 15:05-16:35	Edu 1 Radiation Gynecologic Oncology 15:05-16:35	Oral 1 Cervical Cancer Screening/CIN 15:05-16:35					
15:30								
16:00	Break 16:35-16:55							
16:30	Sympo 2 Cervical Cancer Screening in Asia 16:55-18:25	Edu 2 Gyne-Oncologic Pathology 16:55-18:25	Oral 2 Endometrial Hyperplasia/Cancer 16:55-18:15					
17:00								
17:30								
18:00								
18:30								
19:00	Welcome Reception 19:00-21:00							

Friday, October 11

Friday, October 11					
	GBR A	GBR B	205	206-207	GBR C & Lobby
08:30	Sympo 3 Revised FIGO Stage of Cervix Cancer & Related Issues 08:30-10:00	Sympo 4 Endometrial Cancer Update 08:30-10:00		Edu 3 ERAS 08:30-09:05	Exhibition & Poster Display
09:00				Special 1 Molecular Dissection of Ovarian Clear Cell Carcinoma 09:10-10:00	
09:30					
10:00	Break 10:00-10:20				
10:30	Plenary 2 Surgical Issues in Gynecologic Oncology Field 10:20-12:10				
11:00					
11:30					
12:00	Break 12:10-12:20				
12:30	Special Symposium 2 Sponsored by Roche Luncheon 12:20-13:10				
13:00	Plenary 3 PAPRI, Immuno-oncology and Beyond 13:10-14:40				
13:30					
14:00					
14:30	Break 14:40-15:00				
15:00	Sympo 5 Hereditary Breast and Ovarian Cancer in Asia 15:00-16:30	Sympo 6 MIS in gynecologic cancer management 15:00-16:30	Ovarian Cancer Roundtable Session of Chinese Gynecologic Oncologists 15:00-17:00	Oral 3 TR in Ovarian Cancer 15:00-16:30	
15:30					
16:00					
16:30	Break 16:30-16:50		15:00-17:00	Break 16:30-16:50	
17:00	Edu 4 Surgical and Molecular Tumor Board 16:50-18:20	Special 2 ASGO-AOGIN Joint Session: How to Collaborate to Eradicate Cervical Cancer in Asia-Pacific Region 16:50-18:20		Oral 4 Issues in Surgical Treatment 16:50-18:10	
17:30					
18:00					
18:30					
19:00	Banquet 18:45-21:00				
19:30	PBR A, B				

Saturday, October 12

Saturday, October 12				
	GBR A	204-205	206-207	GBR C & Lobby
08:30	Special 3 International Research Collaboration through GCIG 08:30-10:00	Poster Discussion 08:30-08:50	Oral 5 TR & Hereditary 08:30-10:00	Exhibition & Poster Display
09:00				
09:30				
10:00	Break 10:00-10:20			
10:30	Special 4 Clinical Trial in Asia: Can We Make a Quantum Jump? 10:20-11:05	Film 1A 10:20-11:05	Oral 6 Cervical Cancer & GTN Treatment 10:20-11:30	
11:00				
11:30	Edu 6 Training Session for Young Investigator and Research Nurse 11:10-12:00	Film 1B 11:05-11:50		
12:00			Break 12:00-12:10	
12:30	Special Symposium 3 Sponsored by Takeda Luncheon 12:10-13:00			
13:00	Sympo 7 Fertility Preservation Upfront 13:00-14:00	Edu 7 Imaging in Ovarian Cancer Practice 13:00-14:00	Special 5 From Good Research to Good Publication 13:00-14:00	
13:30				
14:00	Sympo 8 Chemotherapy and Related Supportive Care 14:05-15:05	Edu 8 Ovarian Cancer Surgery 14:05-15:05	Oral 7 Medical Treatment in Ovarian Cancer 14:05-15:05	
14:30				
15:00	Closing Ceremony 15:05-15:20			
15:30				
16:00				
16:30				
17:00				
17:30				
18:00				
18:30				
19:00				
19:30				

08:00-14:55 [Shingo Fujii Medical Academy]

Room 204, 205

Organizer: Shingo Fujii (Kyoto University, Japan)
Co-organizer: Joo-Hyun Nam (University of Ulsan, Korea)
 Kung-Liahng Wang (Taitung Mackay Memorial Hospital, Taiwan)
Commentators: Young Tak Kim (University of Ulsan, Korea)
 Sang-Yoon Park (National Cancer Center, Korea)
 Yoon Soon Lee (Kyungpook National University Chilgok Hospital, Korea)
 Noriaki Sakuragi (Hokkaido University, Japan)
 Hidetaka Katabuchi (Kumamoto University, Japan)
 Mikio Mikami (Tokai University, Japan)
 Tomoyasu Kato (National Cancer Center Hospital, Japan)
 Masaki Mandai (Kyoto University, Japan)

- 08:00-08:05 Introduction of Shingo Fujii
Soon-Beom Kang (Seoul National University, Korea)
- 08:05-08:40 Robot-assisted laparoscopic nerve sparing radical hysterectomy and bilateral pelvic lymphadenectomy for early cervical cancer
Wu-Chou Lin (China Medical University Hospital, Taiwan)
- 08:40-09:15 Surgical anatomy of para-vesico vaginal space
Rongyu Zang (Zhongshan Hospital, Fudan University, China)
- 09:15-09:50 Example video for discussion
- 09:50-10:25 Anatomy of the posterior-leaf of the vesicouterine ligament
Tetsu Asai & Mikio Mikami (Shin-Yurigaoka General Hospital, Japan)
- 10:25-10:45 Break
- 10:45-11:20 Preservation of rectal branches of Inferior hypogastric plexus during resection of rectovaginal ligament
Yoon Soon Lee (Kyungpook National University Chilgok Hospital, Korea)
- 11:20-11:55 Nerve-sparing radical hysterectomy
Yasushi Kotani (Kindai University Hospital, Japan)
- 11:55-12:30 Anatomy and procedure performed safely of the vesicouterine ligament
Kentaro Sekiyama (Kitano Hospital, Japan)
- 12:30-12:35 Break

- 12:35-13:45 Luncheon & Opening Ceremony
- 13:45-14:20 Reduced-port laparoscopic nerve sparing (type C1) radical hysterectomy
Dae-Yeon Kim (University of Ulsan, Korea)
- 14:20-14:55 A modified technique for nerve-sparing radical hysterectomy
Kittipat Charoenkwan (Chiang Mai University, Thailand)

12:35-12:55 [Special Symposium 1]
Sponsored by AstraZeneca

GBR A, B

Chair: Jong-Hyeok Kim (University of Ulsan, Korea)

12:35-12:55 Evolving of BRCA mutated ovarian cancer treatment: study 19
Richard Penson (Massachusetts General Hospital, USA)

THURSDAY



AstraZeneca Korea Oncology

13:25-13:45 [Opening Ceremony] GBR A, B

Opening remarks: Seung Cheol Kim (Ewha Womans University, Korea)

Congratulatory remarks: Hee-Sug Ryu (Ajou University, Korea)

13:45-14:45 [Plenary Session 1] President Invited Lectures GBR A, B

Chair: Hee-Sug Ryu (Ajou University, Korea)

Ikuo Konishi (National Hospital Organization Kyoto Medical Center, Japan)

13:45-14:15 Toward precision medicine: evolution of global distributed research network in Korea

Rae-Woong Park (Ajou University, Korea)

14:15-14:45 Artificial intelligence in medicine

Yoon-Sup Choi (Digital Healthcare Institute, Korea)

15:05-16:35 [Symposium 1] GBR B**Rare Gynecologic Cancers: What is New?**

Chair: Hextan Ngan (The University of Hong Kong, Hong Kong)

Taek-Sang Lee (Seoul National University, Korea)

15:05-15:20 Ovarian clear cell carcinoma

Wen Yee Chay (National Cancer Centre Singapore, Singapore)

15:20-15:35 Uterine leiomyosarcoma

E Sun Paik (Samsung Medical Center, Korea)

15:35-15:50 Trophoblastic disease update

Yang Xiang (Peking Union Medical College Hospital, China)

15:50-16:05 Germ cell tumor

Hiroyuki Fujiwara (Jichi Medical University, Japan)

16:05-16:20 Low grade serous carcinoma

Miseon Kim (CHA University, Korea)

16:20-16:35 Discussion

15:05-16:35 [Education Session 1] Room 204, 205**Radiation Gynecologic Oncology**

Chair: Joo-Young Kim (National Cancer Center, Korea)

Won Park (Samsung Medical Center, Korea)

15:05-15:25 Locally advanced cervical cancer with lymph node positive on image: chemoradiation first?

Hyun-Cheol Kang (Seoul National University, Korea)

15:25-15:45 What is the best sequence of chemotherapy and radiotherapy in locoregionally advanced endometrial cancer?

Jihye Cha (Yonsei University, Korea)

15:45-16:05 The role of brachytherapy in the treatment of cervical cancer

Chomporn Sitathanee (Mahidol University, Thailand)

16:05-16:25 MRI-guided brachytherapy in cervical cancer in Korea

Yeon Joo Kim (National Cancer Center, Korea)

16:25-16:35 Discussion

15:05-16:35 [Oral 1] Cervical Cancer Screening/CIN Room 206, 207

Chair: Jae Yun Song (Korea University, Korea)

Tae Joong Kim (Samsung Medical Center, Korea)

15:05-15:15 Identification of key genes and microRNAs in cervical cancer progression by integrated bioinformatics analysis

Yuqin Zang (Tianjin Medical University, China)

15:15-15:25 The distribution and prevalence of high-risk human papillomavirus of women in western China: a meta-analysis

Mengpei Zhang (Sichuan University, China)

15:25-15:35 Differences in the results of evaluation of quality assurance between the two methods of provision of population-based cervical cancer screening in Japan

Eiko Aoki (International University of Health and Welfare, Mita Hospital, Japan)

15:35-15:45 A prospective randomized controlled study to compare thermal ablation with cryotherapy in cervical cancer screening

Dipanwita Banerjee (Chittaranjan National Cancer Institute, India)

15:45-15:55 Application of TERC and P16 FISH in triage of ASCUS

Ying Li (Zhejiang University, China)

15:55-16:05 Risk factors for type-specific HPV persistence after conization

Yung-Taek Ouh (Korea University, Korea)

16:05-16:15 Abnormal endocervical curettage (ECC) result is an independent risk factor of positive margins in conization specimen

Jian An (Fujian Medical University, China)

16:15-16:25 GX-188E, a therapeutic HPV vaccine, in combination with imiquimod or IL-7-HYFC for treatment of HPV-16 or HPV-18 related cin 3: results from phase 2 study

Sungjong Lee (The Catholic University, Korea)

16:25-16:35 Quality assessment of websites providing information on HPV vaccines in Thailand

Naratassapol Likitdee (Khon Kaen University, Thailand)

16:55-18:25 [Symposium 2] Cervical Cancer Screening in Asia **GBR B**

Chair: *Jae-Kwan Lee (Korea University, Korea)*
Eiko Aoki (International University of Health and Welfare, Mita Hospital, Japan)

- 16:55-17:10 The distribution and prevalence of human papillomavirus in women in mainland China
Rutie Yin (West China Second University Hospital of Sichuan University, China)
- 17:10-17:25 Korean national cervical cancer screening program
Mina Suh (National Cancer Center, Korea)
- 17:25-17:40 Japanese population-based cervical cancer management system
Kumiko Saika (National Cancer Center, Japan)
- 17:40-17:55 Cervical cancer screening in India
Seema Singhal (All India Institute of Medical Sciences, India)
- 17:55-18:10 Cervical cancer screening in Myanmar
Myint Myint Thinn (Central Women's Hospital, Myanmar)
- 18:10-18:25 Discussion

16:55-18:25 [Education Session 2] Gyne-Oncologic Pathology **Room 204, 205**

Chair: *Hidetaka Katabuchi (Kumamoto University, Japan)*
Yong-Beom Kim (Seoul National University, Korea)

- 16:55-17:15 Squamous cell carcinoma of the vulva and its precursors: does p53/p16 status matter?
Kyu-Rae Kim (University of Ulsan, Korea)
- 17:15-17:35 Mucinous ovarian tumor and pseudomyxoma
Chong Woo Yoo (National Cancer Center, Korea)
- 17:35-17:55 Molecular pathology and immunohistochemistry of gynecologic malignancy
Daichi Maeda (Osaka University, Japan)
- 17:55-18:15 Pathology of ovarian cancer precursors
Ren-Chin Wu (Chang Gung Memorial Hospital, Taiwan)
- 18:15-18:25 Discussion

16:55-18:15 [Oral 2] Endometrial Hyperplasia/Cancer **Room 206, 207**

Chair: *Jaeman Bae (Hanyang University, Korea)*
Sungjong Lee (The Catholic University of Korea, Korea)

- 16:55-17:05 Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean gynecologic oncology group study
Mi Kyoung Kim (CHA University, Korea)
- 17:05-17:15 Diagnostic accuracy of M² Pap™ in women with abnormal uterine bleeding for endometrial cancer: preliminary report of a multicenter validating confirmatory study
Hung-Cheng Lai (Taipei Medical University, Taiwan)
- 17:15-17:25 The effect of combined progesterone and GnRH agonist on the growth of endometrial cancer cells
Kyungjoo Cho (Gachon University, Korea)
- 17:25-17:35 Effect of megestrol acetate plus metformin as fertility-sparing treatment for patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer. A randomized controlled trial
Bingyi Yang (Obstetrics and Gynecology Hospital of Fudan University, China)
- 17:35-17:45 The oncologic outcome after fertility-sparing hormonal management more than 9 months treatment for early stage endometrioid endometrial cancer
Su Hyun Chae (Konkuk University, Korea)
- 17:45-17:55 Prolactin enhances the proliferation of endometrial glandular cells and endometrial cancer cells in conjunction with estradiol via regulation of prolactin receptor and estrogen receptor
Munekage Yamaguchi (Kumamoto University, Japan)
- 17:55-18:05 Selecting endometrial cancer patients for high risk of recurrence
Kailash Narayan (University of Melbourne, Australia)
- 18:05-18:15 Using deep learning with convolutional neural network approach to identify the invasion depth of myometrium under MR images in early stage of endometrial cancer ~ a pilot study of TSGH in Taiwan
Cheng-Chang Chang (National Defense Medical Center, Taiwan)

Friday, October 11

08:30-10:00 **[Symposium 3]**
Revised FIGO Stage of Cervix Cancer & Related Issues GBR A

Chair: Neerja Bhatla (All India Institute of Medical Sciences, India)
Jatupol Srisomboon (Chiang Mai University, Thailand)

- 08:30-08:45 Validating new (2018) FIGO staging of cervix cancer
Kailash Narayan (University of Melbourne, Australia)
- 08:45-09:00 Pathologic perspectives in revised FIGO
Hyojin Kim (Seoul National University, Korea)
- 09:00-09:15 Status of less-radical surgery in Japan
Takahide Arimoto (Toranomon Hospital, Japan)
- 09:15-09:30 Predictive models for metastasis and recurrence after radical hysterectomy in patients with early-stage cervical cancer
Kittipat Charoenkwan (Chiang Mai University, Thailand)
- 09:30-09:45 Surgical staging in advanced stage
Chel Hun Choi (Samsung Medical Center, Korea)
- 09:45-10:00 Discussion

08:30-10:00 **[Symposium 4] Endometrial Cancer Update** GBR B
Chair: Duk-Soo Bae (Samsung Medical Center, Korea)
Qi Zhou (Chongqing University, China)

- 08:30-08:50 How to avoid futile LND in early stage endometrial cancer
Sokbom Kang (National Cancer Center, Korea)
- 08:50-09:10 LND issues in endometrial cancer
Hidemichi Watari (Hokkaido University, Japan)
- 09:10-09:30 Molecular classification of endometrial cancer
Kidong Kim (Seoul National University, Korea)
- 09:30-09:50 Preservation of ovary in the management of endometrial carcinoma
Kun Song (Shandong University, China)
- 09:50-10:00 Discussion

08:30-09:05 **[Education Session 3] ERAS** Room 206, 207
Chair: Dae-Sik Seo (University of Ulsan, Korea)

- 08:30-08:45 Pre and postoperative management in gynecologic cancer surgery with planned bowel resection
Jung Myun Kwak (Korea University, Korea)

- 08:45-09:00 Pain management and anesthetic issue
Jin-Tae Kim (Seoul National University, Korea)

- 09:00-09:05 Discussion

09:10-10:00 **[Special Session 1]**
Molecular Dissection of Ovarian Clear Cell Carcinoma Room 206, 207

Chair: Aikou Okamoto (The Jikei University, Japan)
Jeong-Won Lee (Samsung Medical Center, Korea)

- 09:10-09:25 Ovarian clear cell carcinoma: molecular characterization of sensitivity to platinum-based chemotherapy
Masataka Takenaka (The Jikei University, Japan)
- 09:25-09:40 Molecular profiling of ovarian clear cell carcinomas: implications for therapy
Ruby Huang (National Taiwan University, Taiwan)
- 09:40-09:55 Genomics to immunotherapy of ovarian clear cell carcinoma
Katsutoshi Oda (The University of Tokyo, Japan)
- 09:55-10:00 Discussion

10:20-12:10 **[Plenary Session 2]**
Surgical Issues in Gynecologic Oncology Field GBR A, B

Chair: Daisuke Aoki (Keio University, Japan)
Young-Tae Kim (Yonsei University, Korea)

- 2nd debulking in epithelial ovarian cancer**
- 10:20-10:35 Surgery for recurrent ovarian cancer. Evidence from DESKTOP series and others
Andreas du Bois (Kliniken Essen-Mitte, Germany)
- 10:35-10:50 GOG 213 surgical part
Robert Coleman (University of Texas MD Anderson Cancer Center, USA)
- 10:50-11:05 Selection criteria and principles for 2nd debulking surgery: expert point of view
Dennis Chi (Memorial Sloan Kettering Cancer Center, USA)
- 11:05-11:15 Discussion
- Surgical approach in early stage cervical cancer after LACC**
- 11:15-11:30 Real problems of laparoscopic radical hysterectomy
Joo-Hyun Nam (University of Ulsan, Korea)
- 11:30-11:45 Asian viewpoint
Mikio Mikami (Tokai University, Japan)
- 11:45-12:00 American and the other world viewpoint
Mario Leitao (Memorial Sloan Kettering Cancer Center, USA)
- 12:00-12:10 Discussion

13:10-14:40 **[Plenary Session 3]**
PAPRI, Immuno-Oncology and Beyond GBR A, B

Chair: Seung Cheol Kim (Ewha Womans University, Korea)
Xing Xie (Zhejiang University, China)

- 13:10-13:30 PARP inhibition in ovarian cancer: is it time for a paradigm shift?
Richard Penson (Massachusetts General Hospital, USA)
- 13:30-13:50 Prevalence of BRCA mutation and real world experience of PAPRI
Byoung-Gie Kim (Samsung Medical Center, Korea)
- 13:50-14:10 Biomarkers for immunotherapy usage in gynecologic cancer
Wei Zhou (Merck Research Laboratories, USA)
- 14:10-14:30 Novel and emerging agents under development for gynecologic cancers
Wen Yee Chay (National Cancer Centre Singapore, Singapore)
- 14:30-14:40 Discussion

15:00-16:30 **[Symposium 5]**
Hereditary Breast and Ovarian Cancer in Asia GBR A

Chair: Takayuki Enomoto (Niigata University, Japan)
Wen-Fang Cheng (National Taiwan University, Taiwan)

- 15:00-15:20 Establishing BRCA consortium in Asia
Sung-Won Kim (Daerim St. Mary's Hospital, Korea)
- 15:20-15:40 Strategies of genetic test and counseling in Asia
Masayuki Sekine (Niigata University, Japan)
- 15:40-16:00 Clinical impact of hereditary predisposition in gynecologic cancer
Myong-Cheol Lim (National Cancer Center, Korea)
- 16:00-16:20 A need of Asian guidelines for the management of BRCA carrier
Arb-aroon Lertkhachonsuk (Mahidol University, Thailand)
- 16:20-16:30 Discussion

15:00-16:30 **[Symposium 6]**
MIS in Gynecologic Cancer Management GBR B

Chair: Nobuo Yaegashi (Tohoku University, Japan)
Soo Young Hur (The Catholic University of Korea, Korea)

- 15:00-15:15 Sentinel lymph node biopsy in cervical and vulvar cancer
Mario Leitao (Memorial Sloan Kettering Cancer Center, USA)

- 15:15-15:30 Robotic approach for high-risk endometrial cancer
Jiheum Paek (Ajou University, Korea)
- 15:30-15:45 Sentinel lymph node staging experience in Thailand
Nuttavut Kantathavorn (HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Thailand)
- 15:45-16:00 Two-step sentinel lymph node mapping strategy in endometrial cancer
Sang-Wun Kim (Yonsei Cancer Center, Korea)
- 16:00-16:15 Current role of minimally invasive surgery for ovarian cancer
Jeong-Yeol Park (University of Ulsan, Korea)
- 16:15-16:30 Discussion

15:00-17:00 **Ovarian Cancer Roundtable Session of Chinese Gynecologic Oncologists** Room 205

- 15:00-15:10 Opening
Xing Xie (Zhejiang University, China)
Rongyu Zang (Fudan University Zhongshan Hospital, China)
- Part 1**
Jihong Liu (Sun Yat-Sen University Cancer Center, China)
- 15:10-15:40 Cornerstone: recent advances in surgery of ovarian cancer
Jianqing Zhu (Zhejiang Cancer Hospital, China)
- 15:40-16:00 Discussion
Discussion Leader: Yang Xiang (Peking Union Medical College Hospital, China)
- Part 2**
Qi Zhou (Chongqing University, China)
- 16:00-16:30 Milestone: advances in targeted therapy in ovarian cancer
Rutie Yin (West China Second University Hospital of Sichuan University, China)
- 16:30-16:50 Discussion
Discussion Leader: Yang Xiang (Peking Union Medical College Hospital, China)
- 16:50-17:00 Closing
Xing Xie (Zhejiang University, China)
Rongyu Zang (Fudan University Zhongshan Hospital, China)

15:00-16:30 [Oral 3] TR in Ovarian Cancer Room 206, 207
 Chair: Sarikapan Wilailak (Ramathibodi Hospital, Thailand)
 Ting-Chang Chang (Chang Gung Memorial Hospital at Linkou, Taiwan)

15:00-15:10 Antitumor effect of FGFR inhibitor AZD4547 in ovarian cancer cells
 Tae-Kyu Jang (Keimyung University, Korea)

15:10-15:20 Survival prognosis of uterine-preserving surgery on stage I primary mucinous epithelial ovarian carcinoma
 Kaname Uno (Nagoya University, Japan)

15:20-15:30 YAP silencing using dobutamine-PLGA nanoparticle as a new therapeutic strategy for ovarian cancer
 Ju-Won Roh (Dongguk University, Korea)

15:30-15:40 Tyrosine kinase receptor TIE-1 mediates cell growth by regulating PI3K/Akt signaling pathway in PI3K-high-expressing ovarian cancer.
 Xuewei Zhang (Tohoku University, Japan)

15:40-15:50 First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.
 Wen Yee Chay (National Cancer Centre Singapore, Singapore)

15:50-16:00 The roles of androgen receptor in chemosensitivity in serous ovarian cancer
 Hung-Chun Fu (Chang Gung Memorial Hospital, Taiwan)

16:00-16:10 Cancer stem cell (CD133, CD44 and ALDH1A1) markers as prognostic factors on epithelial ovarian cancer
 Nugraha Pelupessy (University of Hasanuddin, Indonesia)

16:10-16:20 Low expression of gamma-glutamyl transpeptidase 1 is an independent poor prognostic factor associated with up-regulation of immune suppressive genes and EMT-related genes in ovarian clear cell carcinoma
 Hiroshi Asano (Hokkaido University, Japan)

16:20-16:30 The role Of Akt2, and CA-125 serum levels as predictors for cytoreduction in epithelial ovarian cancer surgery
 Yudi Mulyana Hidayat (Padjajaran University, Indonesia)

16:50-18:20 [Education Session 4] GBR A
Surgical and Molecular Tumor Board
 Chair: Sang Young Ryu (National Cancer Center, Korea)
 Xiaoping Li (Peking University people's hospital, China)

16:50-17:00 Case presentation: cervix cancer
 U Chul Ju (Chonnam National University, Korea)

17:00-17:15 Comments on of the cervical cancer management
 Hung-Cheng Lai (Taipei Medical University, Taiwan)

17:15-17:20 Discussion

17:20-17:30 Case presentation: endometrial cancer
 Yiqin Wang (Peking University People's Hospital, China)

17:30-17:45 Comments on various aspects of the case management
 Janice Kwon (University of British Columbia, Canada)

17:45-17:50 Discussion

17:50-18:00 Case presentation: epithelial ovarian cancer
 Won-Kyo Shin (National Cancer Center, Korea)

18:00-18:15 Comments on various aspects of the case management
 Masaki Mandai (Kyoto University, Japan)

18:15-18:20 Discussion

16:50-18:10 [Oral 4] Issues in Surgical Treatment Room 206, 207
 Chair: Kung-Liahng Wang (Taitung Mackay Memorial Hospital, Taiwan)
 Yoon-Soon Lee (Kyungpook National University, Korea)

16:50-17:00 Risk factors for lymph node metastasis according to LVSI in apparent uterine-confined endometrial cancer
 Joo-Hyuk Son (Ajou University, Korea)

17:00-17:10 Development of novel diagnosis method of uterine cancer using lymph node metastasis predictive biomarker for more personalized lymphadenectomy
 Emiko Yoshida (Juntendo University, Japan)

17:10-17:20 Comparison of ROMA algorithm and CA 125 as tools for discriminate benign ovarian tumor and early stage ovarian cancer according to imaging tumor subtypes that connected to postoperative histopathologic findings
 Youngjae Lee (University of Ulsan, Korea)

17:20-17:30 Inadvertent ovarian malignancy following operative laparoscopy of adnexal masses: university malaya medical centre experience
 Muhammad Asyraf Azizan (University Malaya Medical Center, Malaysia)

17:30-17:40 Analysis of factors influencing the recurrence and fertility outcomes of ovarian borderline tumors
 Zhengmao Zhang (Hebei Medical University, China)

17:40-17:50 The effect of pelvic and para-aortic lymphadenectomy for clinically-apparent stage I endometrioid epithelial ovarian carcinoma

Masato Yoshihara (Nagoya University, Japan)

17:50-18:00 Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary

Shohei Iyoshi (Nagoya University, Japan)

18:00-18:10 Knowledge, attitude and practices of gynecologists in a tertiary hospital on preoperative bowel preparation

Romelyn Imperio-Onglao (Philippine General Hospital, Philippines)

**16:50-18:20 [Special Session 2] ASGO-AOGIN Joint Session: GBR B
How to Collaborate to Eliminate Cervical Cancer in Asia-Pacific Region**

Chair: EH Tay (AOGIN President, Singapore)

Young-Tak Kim (University of Ulsan, Korea)

16:50-17:10 Elimination of cervical cancer: global overview and prospects for Asia

Neerja Bhatla (All India Institute of Medical Sciences, India)

17:10-17:30 VIA with picture as one option strategy in increasing the cervical cancer screening coverage in low resource setting area

Dwiana Ocviyanti (Universitas Indonesia AOGIN, Indonesia)

17:30-17:50 HPV test as a primary cervical cancer screening

Warner Huh (University of Alabama at Birmingham, USA)

17:50-18:10 Cost-effectiveness of primary HPV test and triage test in cervical cancer screening

Wichai Termrungruanglert (Chulalongkorn University, Thailand)

18:10-18:20 Discussion

SCIENTIFIC PROGRAM

Saturday, October 12

36

Saturday, October 12

08:30-10:00 **[Special Session 3]** **International Research Collaboration through GCIG** **GBR A**

Chair: Kazunori Ochiai (Shin-Yurigaoka General Hospital, Japan)
Jae-Weon Kim (Seoul National University, Korea)

08:30-08:45 Role of GCIG on changing the practice in gynecologic cancer patients
Keiichi Fujiwara (Saitama Medical University International Medical Center, Japan)

08:45-09:00 Operation and harmonization for international clinical trial management
Yusuke Kajimoto (Gynecologic Oncology Trial and Investigation Consortium of North Kanto, Japan)

09:00-09:15 Cervix & CCRN
Sang-Young Ryu (National Cancer Center, Korea)

09:15-09:30 Ovarian cancer
Rongyu Zang (Fudan University Zhongshan Hospital, China)

09:30-09:45 Endometrial cancer
Jae-Weon Kim (Seoul National University, Korea)

09:45-10:00 Discussion

08:30-10:00 **[Oral 5] TR & Hereditary** **Room 206, 207**

Chair: Efren Domingo (University of The Philippines, Philippines)
Dae-Hoon Jeong (Inje University, Korea)

08:30-08:40 Development and preclinical testing of patient-derived xenograft(PDX) models for uterine cancer
Soo Young Jeong (Samsung Medical Center, Korea)

08:40-08:50 LncRNA RP11-395G23.3, as a competitive endogenous RNA, regulate PTEN expression by sponging miR-205-5p in the progression of endometrial cancer
Weijuan Xin (Obstetrics and Gynecology Hospital of Fudan University, China)

08:50-09:00 Calcium channel CAV1.3 participates in epithelial-mesenchymal transition of endometrial cancer cells induced by transforming growth factor β
Yibo Dai (Peking University, China)

09:00-09:10 Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers
Jeong-Won Lee (Samsung Medical Center, Korea)

09:10-09:20 Genomic comparison of endometrioid endometrial carcinoma and its precancerous lesions
Xuan Zong (Peking Union Medical College, China)

09:20-09:30 Clinicopathologic significance of mismatch repair protein expression in endometrial cancer
Mi-Kyung Kim (Ewha Womans University, Korea)

09:30-09:40 Long term outcome of young patients with mismatch-repair deficient endometrial carcinoma
Mandy Man Yee Chu (The University of Hong Kong, Hong Kong)

09:40-09:50 Mutation landscape of germline and somatic BRCA1/2 genes in high-grade serous ovarian cancer patients
Kyung Jin Eoh (Yonsei University, Korea)

09:50-10:00 Hormone replacement therapy after premature surgical menopause and health services utilization
Ji-Hyun Jang (The University of British Columbia, Canada)

08:30-08:50 **[Poster Discussion]** **Room 204, 205**

08:30-08:50 Selected poster discussion: merits and demerits
Yoo-Young Lee (Samsung Medical Center, Korea)

09:00-10:00 **[Education Session 5]** **Uterine and Cervical Cancer Surgery** **Room 204, 205**

Chair: Ju Won Roh (Dongguk University, Korea)
Joong Sub Choi (Hanyang University, Korea)

09:00-09:15 Radical hysterectomy
Dae-Yeon Kim (University of Ulsan, Korea)

09:15-09:30 LEER
Hee-Seung Kim (Seoul National University, Korea)

09:30-09:45 TMMR for cervical cancer
Rainer Kimmig (University Hospital Essen, Germany)

09:45-10:00 PMMR for endometrial cancer
Rainer Kimmig (University Hospital Essen, Germany)

10:20-11:05 **[Special Session 4]** **Clinical Trial in Asia: Can We Make a Quantum Jump?** **GBR A**

Chair: Wen Yee Chay (National Cancer Centre Singapore, Singapore)
Jae-Hoon Kim (Yonsei University, Korea)

10:20-10:35 Overview of the current status of clinical trials in Asia
Kosei Hasegawa (Saitama Medical University, Japan)

10:35-11:05 Discussion

10:20-11:30 [Oral 6] Cervical Cancer & GTN Treatment Room 206, 207

Chair: Sang Hoon Kwon (Keimyung University, Korea)
Dong Choon Park (The Catholic University of Korea, Korea)

- 10:20-10:30 Ovarian metastasis in early-stage cervical cancer: a large single institution study
Kittipat Charoenkwan (Chiang Mai University, Thailand)
- 10:30-10:40 Impact of learning curve on the survival of abdominal or minimally invasive radical hysterectomy for early stage cervical cancer
Hwajung Lee (Yonsei University, Korea)
- 10:40-10:50 Impact of obesity on clinical outcomes in patients with early-stage cervical cancer after radical hysterectomy with pelvic node dissection
Kittinun Leetanaporn (Prince of Songkhla University, Thailand)
- 10:50-11:00 Post-irradiation PD-L1 expression predicts better prognosis after carbon ion radiotherapy in uterine cervical adenocarcinoma
Moito Iijima (Keio University, Japan)
- 11:00-11:10 Comparisons of radiotherapy outcomes in cervical squamous cell carcinoma stage IIIB with and without lymph node enlargement
Fitriyadi Kusuma (University of Indonesia, Indonesia)
- 11:10-11:20 Clinical significance of centralized surveillance of hydatidiform mole: five years' experience from a regional hospital in China
Lan-zhou Jiao (Dalian Medical University, China)
- 11:20-11:30 Gestational trophoblastic neoplasia: determinants of outcome
Seema Singhal (All India Institute of Medical Sciences, India)

10:20-11:05 [Film 1A] Room 204, 205

Chair: Xiaohua Wu (Fudan University Shanghai Cancer Center, China)
Keun Ho Lee (The Catholic University of Korea, Korea)

- 10:20-10:29 Laparoscopic radical hysterectomy without uterine manipulator for early stage cervical cancer
Huaiwu Lu (Sun Yat-sen Memorial Hospital, China)
- 10:29-10:38 Clinical anatomy required in identifying pelvic autonomic nerve system
Yasuhiko Shiki (Osaka Rosai Hospital, Japan)

10:38-10:47 Single-port laparoscopic radical trachelectomy with fluorescent image-guided sentinel lymph node dissection
Sang Wun Kim (Yonsei University, Korea)

10:47-10:56 Robotic single-port surgical staging for endometrial cancer using da Vinci SP® surgical system
Jung Hun Lee (Kyungpook National University, Korea)

10:56-11:05 Laparoscopic primary repair of duodenal perforation after laparoscopic para-aortic lymphadenectomy
Hyeon Myeong Hong (Hanyang University, Korea)

11:05-11:50 [Film 1B] Room 204, 205

Chair: Andri Andrijono (University of Indonesia, Indonesia)
Noh-Hyun Park (Seoul National University, Korea)

- 11:05-11:14 Cervical cancer surgery
Zhengmao Zhang (RGCIIRC, DELHI, China)
- 11:14-11:23 Laparoscopic extraperitoneal systematic pelvic and PARA-aortic lymphadenectomy
Supachai Raungkaewmanee (National Cancer Institute, Thailand)
- 11:23-11:32 Nerve sparing modified laparoscopic radical hysterectomy with vaginal cuff closure and without uterine manipulator
Dae-yeon Kim (University of Ulsan, Korea)
- 11:32-11:41 Single-site robotic staging surgery for early stage ovarian cancer
Ji Geun Yoo (The Catholic University, Korea)
- 11:41-11:50 Combined technique of single-site robot and laparoscopy in comprehensive staging operation of endometrial cancer
Bo-Ra Lee (Chung-Ang University, Korea)

11:10-12:00 [Education Session 6] GBR A
Training Session for Young Investigator and Research Nurse

Chair: Rongyu Zang (Fudan University Zhongshan Hospital, China)
Byoung-Gie Kim (Samsung Medical Center, Korea)

- 11:10-11:25 The Role of the CRC in an investigator initiated trial
Ju Yeon Yi (RCONNECT, Korea)
- 11:25-11:40 The role and environment of research nurse
Noriko Fujiwara (The University of Tokyo, Japan)
- 11:40-11:55 How to start investigator-initiated study?
Jung-Yun Lee (Yonsei University, Korea)
- 11:55-12:00 Discussion

13:00-14:00 **[Symposium 7] Fertility Preservation Upfront** **GBR A**
 Chair: Jihong Liu (Sun Yat-Sen University Cancer Center, China)
 Kimio Ushijima (Kurume University, Japan)

13:00-13:15 Radical trachelectomy for young patients with early cervical cancer: the past and the future
 Jin Li (Fudan University, China)

13:15-13:30 Fertility preserving treatment of early stage endometrial cancer
 Xiaojun Chen (Hospital of Fudan University, China)

13:30-13:45 Fertility preservation in early stage epithelial ovarian cancer
 Hiroaki Kajiyama (Nagoya University, Japan)

13:45-14:00 Fertility preservation for female cancer patients
 Yutaka Osuga (The University of Tokyo, Japan)

13:00-14:00 **[Education Session 7]** **Room 204, 205**
Imaging in Ovarian Cancer Practice

Chair: Jae Hong No (Seoul National University Bundang Hospital, Korea)
 Seung-Su Han (Chung-Ang University, Korea)

13:00-13:15 Imaging study before cytoreductive surgery
 Byung Kwan Park (Samsung Medical Center, Korea)

13:15-13:30 Imaging follow up strategy of ovarian cancer
 Jeong Yeon Cho (Seoul National University, Korea)

13:30-13:45 Functional Imaging of ovarian cancer
 Dae Chul Jung (Yonsei University, Korea)

13:45-14:00 Response evaluation: RECIST & iRECIST on imaging
 Sung Yoon Park (Samsung Medical Center, Korea)

13:00-14:00 **[Special Session 5]** **Room 206, 207**
From Good Research to Good Publication

Chair: Ki Hyung Kim (Pusan National University, Korea)
 Chunling Chen (Peking University, China)

13:00-13:20 Ethical review of the research project
 Yawana Tanapat (Bumrungrad International Hospital, Thailand)

13:20-13:40 Tips for success as a clinical investigator
 Soyi Lim (Gachon University, Korea)

13:40-14:00 Transparency in medical writing
 Seung-Hyuk Shim (Konkuk University, Korea)

14:05-15:05 **[Symposium 8]** **GBR A**
Chemotherapy and Related Supportive Care
 Chair: Suresh Kumarasamy (Penang Medical College, Malaysia)
 Taejin Kim (Konkuk University, Korea)

14:05-14:20 Post chemotherapy quality of life in developing country
 Hariyono Winarto (Universitas Indonesia, Indonesia)

14:20-14:35 Hypersensitivity reactions to carboplatin and paclitaxel: management and oncologic outcomes
 Suwanit Therasakvichya (Mahidol University, Thailand)

14:35-14:50 Hospice care by specialist palliative care team
 Yoon Jung Chang (National Cancer Center, Korea)

14:50-15:05 Pain control in patients with advanced stage cancer
 Seyoung Seo (University of Ulsan, Korea)

14:05-15:05 **[Oral 7]** **Room 206, 207**
Medical Treatment in Ovarian Cancer

Chair: Yong Jung Song (Pusan National University, Korea)
 Kwang-Beom Lee (Gachon University, Korea)

14:05-14:15 Bevacizumab maintenance therapy extended the overall survival for the histopathological mesenchymal transition type of high-grade serous ovarian carcinoma
 Kentaro Ishida (Nagahama Red Cross Hospital, Japan)

14:15-14:25 Additional chemotherapy in epithelial ovarian cancer with residual disease after six cycles of postoperative adjuvant chemotherapy
 Se Ik Kim (Seoul National University, Korea)

14:25-14:35 Preliminary experience of hyperthermic intraperitoneal chemotherapy after debulking surgery for ovarian cancer
 Wei-Chun Chen (Chang Gung Memorial Hospital, Taiwan)

14:35-14:45 Enhanced chemotherapy effects on gynecological cancers by using the combination of lipid bubble and ultrasound
 Kohei Yamaguchi (The University of Tokyo, Japan)

14:45-14:55 Doxorubicin-loaded oligonucleotide conjugated gold nanoparticles: a promising drug delivery system for ovarian cancer
 Hee Kyeong Seo (Soonchunhyang University, Korea)

14:55-15:05 The influence of depression on health utility value in patients with gynecologic cancer: a comparison with physical symptoms and performance status
 Hyemin Yeo (National Cancer Center, Korea)

**14:05-15:05 [Education Session 8] Room 204, 205
Ovarian Cancer Surgery**

*Chair: Chi-Heum Cho (Keimyung University, Korea)
Chih-Ming Ho (Cathay General Hospital, Taiwan)*

14:05-14:20 Surgical technique: radical upper abdominal dissection/
resection
Suk-Joon Chang (Ajou University, Korea)

14:20-14:35 Surgical technique: radical pelvic dissection/resection
Kazuyoshi Kato (Tokyo Medical University, Japan)

14:35-14:50 MSKCC resectability score and selection criteria for primary
debulking surgery
Dennis Chi (Memorial Sloan Kettering Cancer Center, USA)

14:50-15:05 Role of lymphadenectomy in ovarian cancer
Jianqing Zhu (Zhejiang Cancer Hospital, China)

15:05-15:20 [Closing Ceremony] GBR A**POSTER**

Poster Discussion	46
Poster Display	48

Saturday, October 12, 08:30-08:50

Cancer Screening

- PD01 Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection in Zhejiang province, Southeast China
Qiongyan Wu (Zhejiang University, China)
- PD02 Evaluation of cell-free DNA from papanicolaou smear and peripheral blood to detect endometrial cancer
Xuan Zong (Peking Union Medical College, China)

Invasive Cervical Cancer

- PD03 Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma - updated survival outcomes and experience in post radiation surgery
Jiixin Yang (Peking Union Medical College, China)

Epithelial Ovarian Cancer

- PD04 Impact on overall survival of non-specific death in early-stage epithelial ovarian cancer patients: a SEER database analysis
Danian Dai (Sun Yat-Sen University, China)
- PD05 Cost-effectiveness of tumor testing for BRCA mutations in high-grade serous ovarian cancer for PARP inhibitor maintenance therapy
Janice Kwon (University of British Columbia, Canada)
- PD06 Rosiglitazone ameliorates senescence-like phenotypes in ovarian cancer
Jianwen Gao (Osaka University, Japan)
- PD07 Gonadotropin-releasing hormone receptor-targeted near-infrared fluorescence probe for specific recognition and localization of peritoneal metastases of ovarian cancer
Qiyu Liu (Obstetrics and Gynecology Hospital of Fudan University, China)
- PD08 A clinicopathologic multivariate analysis in effects of Intraepithelial carcinoma on patients with mucinous borderline ovarian tumors
Rui-fang Chen (Obstetrics and Gynecology Hospital of Fudan University, China)

Non-epithelial Ovarian cancer

- PD09 Does comprehensive surgical staging determine the oncological outcome of malignant ovarian germ cell tumour?
Anu Joseph (All India Institute of Medical Sciences, India)
- PD10 Salvage therapy for patients with recurrent and persistent malignant ovarian germ cell tumors
Jinhui Wang (Peking Union Medical College, China)

- PD11 Genetic profiling and clonal evolution in ovarian yolk sac tumor
Xuan Zong (Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China)

Rare Tumors including Uterine Sarcoma & GTD

- PD12 Clinical sequencing by todai oncopanel (TOP) for uterine sarcomas
Hirofumi Inaba (The University of Tokyo, Japan)

Fertility Preservation

- PD13 Modified laparoscopic radical trachelectomy for early stage cervical cancer
Xiaoting Ling (Sun Yat-Sen University, China)

Translational Research

- PD14 The role of hyperactive homologous recombination in survival outcomes of platinum treated ovarian carcinoma
Michal M Hoppe (Cancer Science Institute of Singapore, National University of Singapore, Singapore)
- PD15 Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)
Takashi Mitamura (Hokkaido University, Japan)

Poster Display

Cancer Screening

- P001 Challenges of management of gynecological cancer in LMIC
Aliya Begum (Aga Khan University Hospital, Pakistan)
- P002 Evaluation of high-risk human papillomavirus genotyping and non-genotyping assays for cervical cancer screening, a real-world study in China
Binhua Dong (Fujian University, China)
- P003 Distribution of human papillomavirus genotypes in 533 women with cervical lesions in Chongqing, Southwest China
Dongling Zou (Chongqing University Cancer Hospital, China)
- P004 Utility of human papillomavirus L1 capsid protein and HPV test as prognostic markers for cervical intraepithelial neoplasia 2+ in women with persistent ASCUS/LSIL cervical cytology
Eun Young Ki (The Catholic university of Korea, Korea)
- P005 Efficacy of trichloroacetic acid (TCA) compared to cryotherapy in treating patients with positive IVA result
Herdhana Suwartono (INASGO, Indonesia)
- P006 Impact of visual inspection of the cervix after application with acetic acid (VIA) followed by cryotherapy treatment (see and treat approach) for secondary cervical cancer prevention in Patheingyi Township, Myanmar
Htun Lynn Soe (Central Women's Hospital, Myanmar)
- P007 Cervical cancer screening trends and geographical distribution in Japan
Kanako Kono (Keio University Graduate School of Medicine/ National Cancer Center, Japan)
- P008 The effectiveness of human papillomavirus (HPV) self-sampling testing on cervical cancer screening in a community
Kim Seng Law (Tung's Taichung Metro Harbor Hospital, Taiwan)
- P009 Profiling of serum metabolites using MALDI-TOF and Triple-TOF mass spectrometry to develop a screen for ovarian cancer
Mi-Kyung Kim (Ewha Womans University, Korea)
- P010 A correlation of reporting cervical cytology between gravity sedimentation liquid-based cytology and conventional papanicolaou smears
Nattapong Sermsukcharoenchai (Phramongkutklao Hospital, Thailand)

- P011 The American society for colposcopy and cervical pathology (ASCCP) 2017 risk-based colposcopy practice recommendations when applied for Thai women with ASC-US or LSIL cervical cytology
Rattiya Phianpiset (Mahidol University, Thailand)

Pre-invasive Disease of Uterine Cervix

- P012 HPV infection and p16 promoter methylation as predictors of ASC-US/LSIL progression
Dan-Ah chae (Chung-Ang University, Korea)
- P013 Comparison of histological outcomes from pre-menopausal and post-menopausal women with report of cervical cytological abnormality
Eunhyun Lee (Inje University, Korea)
- P014 Expectant management of pregnant and postpartum women with cervical intraepithelial neoplasia
Hidenori Sasa (National Defense Medical College, Japan)
- P015 The risk of high-grade cervical intraepithelial neoplasia (CIN) and cancer in patients aged 65 years or older with abnormal cervical cancer screening test
Hyun-Woong Cho (Korea University, Korea)
- P016 Management of cervical intraepithelial neoplasia 2 in young women
Jooyoung Kim (Seoul National University, Korea)
- P017 Usefulness of human papillomavirus genotyping to predict residual/ recurrent disease after conservative treatment of cervical intraepithelial neoplasia compared with HPV DNA testing
Kouchiro Kawano (Kurume University, Japan)
- P018 The impact of vaginal microbiota on the cervical carcinogenesis
Kyeong A So (Konkuk University, Korea)
- P019 New diagnostic device for cervical dysplasia using electrical impedance imaging
Dong Choon Park (The Catholic University of Korea, Korea)
- P020 Cervical intraepithelial neoplasia-2 of women in their twenties: which is the best management?
Miseon Kim (CHA University, Korea)
- P021 Diagnostic inaccuracy of colposcopy-directed biopsy in women with cytologic high-grade squamous intraepithelial lesion: immediate loop electrosurgical excision procedure may be a better strategy
Se Ik Kim (Seoul National University, Korea)

P022 The role bacille calmette-guerin BCG TO low grade cervical precancerous lesions
Tendi Robby Setia (Hasan Sadikin Hospital, Indonesia)

P023 Cervical intraepithelial neoplasia and risk of gynecologic cancer: a nationwide cohort study
Yung-Taek Ouh (Korea University, Korea)

Pre-invasive Disease and Cancer of Vulvo-Vagina

P024 Basal cell carcinoma of the vulva: a case report
Aubrey Seneris (Philippine General Hospital, Philippines)

P025 The risk factors of high-grade vaginal intraepithelial neoplasia (VaIN) and cancer: single institution experience
Hyun-Woong Cho (Korea University, Korea)

P026 A case report and literature review of primary vaginal NK/T lymphoma
Luo Yan (Sichuan University, China)

P027 Experience of treatment of vulvar malignancies in a regional tertiary centre in Southeast Asia
Qi Maili (KK Women's and Children's Hospital, Singapore)

P028 Recurrent paget's disease of the vulva in a split-thickness graft
Romelyn Imperio-Onglao (Philippine General Hospital, Philippines)

P029 A rare case of invasive vaginal carcinoma post vaginal hysterectomy
Romelyn Imperio-Onglao (Philippine General Hospital, Philippines)

P030 Carcinoma of vulva, case series
Saujanya Karmacharya (IGCS, Civil Service Hospital, Nepal)

P031 Vaginal stripping for vaginal intraepithelial neoplasia (VAIN)
Yu Ka Chai (Queen Mary Hospital, Hong Kong)

Invasive Cervical Cancer

P032 Phase I study of a B cell- and monocyte-based immunotherapeutic vaccine, BVAC-C in human papillomavirus type 16- or 18-positive recurrent cervical Cancer
Chel Hun Choi (Samsung Medical Center, Korea)

P033 Post-surgical prognosis of low and medium-risked cervical cancer and its correlation with adjuvant treatment
Chihiro Ishizawa (The University of Tokyo, Japan)

P034 Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: ancillary analysis of a Korean gynecologic oncology group study (KGOG 1028)
E Sun Paik (Samsung Medical Center, Korea)

P035 BRCA1 immunohistochemistry expression and survival in cervical cancer
E Sun Paik (Samsung Medical Center, Korea)

P036 Pembrolizumab for unresectable recurrent cervical cancer - pilot experience in a tertiary center of Taiwan
Hsiu-Jung Tung (Chang Gung Memorial Hospital Linkou branch, Taiwan)

P037 Long-term results of minimally invasive versus abdominal radical hysterectomy in patients with early cervical cancer
Hyun Park (CHA University, Korea)

P038 Selection criteria and colpotomic approach for safe minimally invasive radical hysterectomy in early-stage cervical cancer
Joo-Hyuk Son (Ajou University, Korea)

P039 Risk factor for the postoperative lymphocele in women with cervical cancer treated with radical hysterectomy and pelvic lymphadenectomy
Jung Hwan Ahn (The Catholic University of Korea, Korea)

P040 Clinical significance of the pattern-based classification in endocervical adenocarcinoma, usual and variants
Jung Mi Byun (Inje University, Korea)

P041 Single port access laparoscopic radical hysterectomy for early-stage cervix cancer running title: SPA LRH for cervical cancer
Kyung Jin Eoh (Yonsei University, Korea)

P042 Clinical characteristics and prognosis of cervical cancer among Filipino women ages 35 years old and below: a retrospective cohort study
Limavel Ann Veloso (Society of Gynecologic Oncologists of the Philippines, Philippines)

P043 Paclitaxel plus cisplatin as adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIb cervical cancer
Mashiro Shimomura (Osaka City University, Japan)

P044 Early experiences of treatment with pembrolizumab in recurrent gynecologic malignancies
Min Chul Choi (CHA University, Korea)

- P045 Profile of trachelectomy in women with early-stage cervical cancer: a nationwide cohort study in Japan
Miwa Yasaka (Tokai University, Japan)
- P046 Pulmonary lymphangitic metastasis in cervical cancer: case series
Myeong Seon Kim (Sungkyunkwan University, Korea)
- P047 Anti-tumor effects of tetraarsenic oxide (TAO, As₄O₆) in human cervical cancer
Myeong Seon Kim (Sungkyunkwan University, Korea)
- P048 Effectiveness of neoadjuvant chemotherapy in cervical carcinoma (FIGO stage IB₂, IIA₂ and IIB)
Ni Ni Thein (Central Women's Hospital, Myanmar)
- P049 A case of primary signet ring cell carcinoma of the uterine cervix treated with CPT-11/S-1 therapy
Rikako Soma (Iwate Medical University, Japan)
- P050 The texture analysis of FDG PET/CT in cervical cancer
Ruri Otaki (Osaka Medical College Hospital, Japan)
- P051 Comparative outcomes between abdominal and tumor-sealing laparoscopic radical hysterectomy in cervical cancer : results from a single surgeon's experience
Sang Il Kim (The Catholic University of Korea, Korea)
- P052 Impact of laparoscopic radical hysterectomy on survival outcome in patients with FIGO stage IB cervical cancer: a matching study of two institutional hospitals in Korea
Se Ik Kim (Seoul National University, Korea)
- P053 Outcome of patients with uterine cervical cancer undergoing radical hysterectomy using the 2018 FIGO staging
Seiya Sato (Iwate Medical University, Japan)
- P054 Learning curve could affect the surgical outcome of radical hysterectomy in cervical cancer
Seongmin Kim (Korea University, Korea)
- P055 A clinicopathological analysis of 2,378 patients with FIGO 2018 stage IB₁/IB₂ cervical cancer by Japanese gynecologic oncology group network (JGOG 1072s)
Shogo Shigeta (Tohoku University, Japan)
- P056 Factors that influence 1 year survival rate in cervical cancer patient at Wahidin Sudirohusodo hospital, Makassar, Indonesia
Suci Amaliah Syarif (Hasanuddin University, Indonesia)
- P057 Corelation between tumor size and neoadjuvant chemotherapy response in cervical cancer stage IB₂ and IIA₂
Syamel Muhammad (Andalas University, Indonesia)
- P058 Prognosis of stage IIIc uterine cervical cancer following hysterectomy and radiotherapy: validation of revised FIGO staging
Won Kyung Cho (Sungkyunkwan University, Korea)
- P059 Significance of tumor size in IB–IIA cervical cancer with pathologic risk factors following hysterectomy
Won Kyung Cho (Sungkyunkwan University, Korea)
- P060 Measures to prevent tumor spillage in laparoscopic surgery and outcome of total laparoscopic and abdominal radical hysterectomy for FIGO 1B₁–2 cervical cancer
Yasuhiko Shiki (Osaka Rosai Hospital, Japan)
- P061 Triplet chemotherapy versus doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer
Yoo-Young Lee (Samsung Medical Center, Korea)
- P062 Value of adjuvant chemotherapy using paclitaxel plus carboplatin after radical surgery with or without radiotherapy in stage IB–IIA cervical adenocarcinoma with risk factors
You Wu (National Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China)
- P063 Prognosis of early-stage neuroendocrine carcinomas of the cervix: study at a Japanese single institute
Yusuke Kobayashi (Keio University, Japan)
- P064 Protective effect of magnesium supplementation on cisplatin-induced renal toxicity in patients with uterine cervical cancer
Yuta Inoue (Osaka City University, Japan)
- P065 Sentinel lymph nodes mapping can predict the state of peritoneal lymph nodes metastasis in early-stage cervical cancer
Zhengmao Zhang (Hebei Medical University, China)

Epithelial Ovarian Cancer

- P066 Olaparib maintenance therapy for the recurrent high-grade serous ovarian carcinoma: a single center experience
Akihiko Ueda (Kyoto University, Japan)
- P067 Serum lactate dehydrogenase is a possible predictor of platinum resistance in ovarian cancer
Asami Ikeda (National Hospital Organization Kyoto Medical Center, Japan)

- P068 The comparative analysis of clinicopathologic characteristics between seromucinous borderline ovarian tumors (SMBOTs) and mucinous borderline ovarian tumors (MBOTs)
Beibei Wu (Obstetrics and Gynecology Hospital of Fudan University, China)
- P069 The outlook of treatment of ovarian clear cell carcinoma (CCC) ? in molecular aspect
Chen-Bin Chang (Chang Gung Memorial Hospital, Taiwan)
- P070 Core immunological functions involved in ovarian clear cell carcinoma discovered by the gene ontology-based immunofunctionome analysis
Cheng-Chang Chang (Tri-Service General Hospital, National Defense Medical Center, Taiwan)
- P071 Differential promoter methylation and expression at RASSF1A between ovarian carcinoma stromal progenitor and cancer cells predict survival outcome of epithelial ovarian cancer patients
Chih-Ming Ho (Cathay General Hospital, Taiwan)
- P072 Outcome of women unexpectedly diagnosed ovary cancer
Ching Yu Cheng (National Taiwan Universtiy, Taiwan)
- P073 Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer and primary peritoneal cancer
Chompunoot Kongsawatvorakul (Ramathibodi Hospital, Thailand)
- P074 Transmembrane G protein coupled receptor 30 (GPR30) gene polymorphisms in Korean women with ovarian cancer: an experimental study
Dae Gy Hong (Kyungpook National University, Korea)
- P075 Real-world experience of olaparib maintenance in high grade serous recurrent ovarian cancer patients with BRCA 1/2 mutation: Korean multicenter study
E Sun Paik (Samsung Medical Center, Korea)
- P076 Clinicopathology characteristics of ovarian clear cell carcinoma patients at Cipto Mangunkusumo hospital on 2010 - 2015
Fitri Adinda Novianti Mahdi (Cipto Mangunkusumo Hospital, Indonesia)
- P077 A case of ovarian serous borderline tumor in a 12-years-old girl
Fumihiko Murakami (The Catholic University of Korea, Japan)
- P078 The myelosuppressive effect and nephrotoxicity of chemotherapies in ovarian cancer patients: a single-center study
Hariyono Winarto (Universitas Indonesia, Indonesia)
- P079 Circulating tumor DNA in epithelial ovarian cancer
Hee Kyoung Song (The Catholic University of Korea, Korea)
- P080 Evaluation of efficacy and safety of bevacizumab for advance and recurrent mullerian carcinoma in our institution.
Hiroaki Matsubara (Osaka City University, Japan)
- P081 Trends and characteristics of epithelial ovarian cancer between Japan and the US: a JSGO?JOG joint study
Hiroko Machida (Tokai University, Japan)
- P082 Malignant brenner tumor of the ovary: a case report
Humbeline Gaboy (Baguio General Hospital and Medical Center, Philippines)
- P083 Identification of cancer-related long non-coding RNAs before and after neoadjuvant chemotherapy in epithelial ovarian cancer
Jaein Kim (Yonsei University, Korea)
- P084 Clinical characteristics predictive of optimal primary cytoreduction in epithelial ovarian malignancy: a five-year retrospective study in a tertiary government Government Hospital
Jehada-Inn Misuari-Alihuiddin (Philippine General Hospital, Philippines)
- P085 A prospective evaluation of tolerability of niraparib dosing based on baseline body weight and platelet count: blinded pooled interim safety data from the NORA Study
Jia Zhang (Fudan University Shanghai Cancer Center, Indonesia)
- P086 The role and regulatory mechanism of CHD4 in epithelial ovarian cancer
Jieyu Wang (Obstetrics and Gynecology Hospital of Fudan University, China)
- P087 Prognostic analysis of splenic parenchymal metastasis in advanced ovarian cancer: does the parenchymal metastasis matter?
Joo-Hyuk Son (Ajou University, Korea)
- P088 Safety and feasibility of preemptive cholecystectomy as part of cytoreductive surgery in advanced ovarian cancer
Joo-Hyuk Son (Ajou University, Korea)
- P089 Risk factors for postoperative morbidity for ovarian cancer patients undergoing primary debulking surgery
Junchen Chen (Peking University People's Hospital, China)
- P090 Preoperative prognostic biomarkers in ovarian cancer
Junchen Chen (Peking University People's Hospital, China)

- P091 A preoperative risk score to predict intraoperative blood loss volume in patients undergoing hysterectomy for ovarian cancer
Junchen Chen (Peking University People's Hospital, China)
- P092 Feasibility of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: preliminary data
Junsik Park (Yonsei University, Korea)
- P093 Chemotherapy response score is a prognostic factor in patients with ovarian cancer who underwent neoadjuvant chemotherapy and interval debulking surgery
Ken Matsukuma (Kurume University, Japan)
- P094 A typical endometriosis associated with ovarian malignancy
Kyeong A So (Konkuk University, Korea)
- P095 Inhibition of pten induces anti-proliferative effect on ovarian cancer cells
Kyungjoo Cho (Gachon University, Korea)
- P096 Modulation of tumor microenvironment by chemotherapy in ovarian cancer
Ling Lim (MacKay Memorial Hospital, Taiwan)
- P097 Impact of pre-operative whey protein infused carbohydrate loading and post-operative early oral feeding in ovarian cancer patients under fast tract surgery setting
Mohd Norazam Mohd Abas (National Cancer Institute, Malaysia)
- P098 Oncologic safety of closed suction technique in removal of huge ovarian cyst
Nam-Kyeong Kim (Seoul National University, Korea)
- P099 Clinical characteristics of ovarian clear cell carcinoma in an Asian cohort
Pearl Tong (NUHS, Singapore)
- P100 Rash and ovarian cancer: a case of a paraneoplastic syndrome
Reya Hurtado (Philippine General Hospital, Philippines)
- P101 Recurrence patterns after treatment of bevacizumab in platinum-sensitive recurrent epithelial ovarian cancer
Se Ik Kim (Seoul National University, Korea)
- P102 Impact of extended cycles of chemotherapy on survival outcome in recurrent epithelial ovarian cancer
Se Ik Kim (Seoul National University, Korea)
- P103 Effect of BRCA mutational status on survival outcome in epithelial primary peritoneal, ovarian, and fallopian tubal cancers: experience on germline BRCA1/2 gene testing at a tertiary institutional hospital in Korea
Se Ik Kim (Seoul National University, Korea)
- P104 Colorectal and urologic surgery in advanced ovarian cancer, who should do it?
Sigit Purbadi (University of Indonesia, Indonesia)
- P105 Does inclusion of pegylated liposomal doxorubicin in the management of progressive or recurrent ovarian cancer improve overall survival?
Sikarn Satitniramai (Mahidol university, Thailand)
- P106 Integration of plasma proteomics and targeted plasma metabolomics data for serous ovarian cancer diagnosis
Somi Oh (Gangnam Kwon's Gynecology Clinics, Korea)
- P107 Impact of intervals between secondary cytoreductive surgery and adjuvant chemotherapy in patients recurrent epithelial ovarian cancer
Soo Young Jeong (Sungkyunkwan University, Korea)
- P108 Mimicker of advanced ovarian cancer - peritoneal tuberculosis
Sze Ki Hui (Hospital Authority, Hong Kong)
- P109 A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku gynecologic cancer unit 104 study)
Tadahiro Shoji (Iwate Medical University, Japan)
- P110 Ovarian cancer stemness: biological and clinical implications for ovarian cancer metastasis and chemoresistance
Takeshi Motohara (Kumamoto University, Japan)
- P111 Clinicopathologic features and prognostic analysis of stage I ovarian clear cell cancer
Tiantian Wang (Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China)
- P112 Creatinin clearance vs glomerular filtration rate in platinum based chemotherapy: which one is the best?
Tofan Utami (FMUI, Indonesia)
- P113 Intraoperative tumor lysis syndrome in a patient with advanced ovarian cancer
Wilasinee Areeruk (Srinakharinwirot University, Thailand)

- P114 Utility of plasma circulating tumor DNA in ovarian cancer monitoring
Yoshiko Nanki (Keio University, Japan)
- P115 Prevalence and predictors of hematological toxicity on adjuvant chemotherapy and the prognosis in geriatric patients with epithelial ovarian cancer: a two-center retrospective cohort study
Yuxi Zhao (Cancer Hospital Chinese Academy of Medical Science and Peking Union Medical College, China)

Non-epithelial Ovarian cancer

- P116 Individualized significance of lymphadenectomy across all age groups and histologies in malignant ovarian germ cell tumors
Jieyu Wang (Obstetrics and Gynecology Hospital of Fudan University, China)
- P117 A case of ovarian mixed germ cell tumor with torsion
Saki Ishii (Sakai City Medical Center, Japan)
- P118 Inferior vena caval syndrom in paraaortic metastatic lesion of ovarian dysgerminoma in pregnancy manage with chemotherapy: a case report
Syamel Muhammad (Andalas University, Indonesia)
- P119 Ovarian mass in a patient with a strong history of cancer
Zheng Yuan Ng (KK Women's and Children's Hospital, Singapore)

Endometrial Hyperplasia, EIN and Endometrial Cancer

- P120 Feasibility of sentinel lymph node sampling in early stage carcinoma endometrium: experience from a developing country
Aswathy G Nath (RCC, Thiruvananthapuram, India)
- P121 Vaginal recurrence in sentinel lymph node biopsy-negative stage ia endometrial carcinoma using near-infrared fluorescence with indocyanine green dye
Bernadette Yap (UP-Philippine General Hospital, Philippines)
- P122 Correlation of preoperative assessment by magnetic resonance imaging and clinicopathologic results in endometrial cancer
Chia-Ying Wu (National Taiwan University Hospital, Taiwan)
- P123 Comparison of laparoscopy and laparotomy for paraaortic lymphadenectomy in women with high-risk endometrial cancer
E Sun Paik (Samsung Medical Center, Korea)
- P124 Tumor size as independent prognostic factor in stage IA endometrioid endometrial adenocarcinoma
Geminelle Co (Philippine General Hospital, Philippines)

- P125 Evaluation of myometrial invasion in type I endometrial cancer using magnetic resonance diffusion weighted imaging
Hariyono Winarto (FKUI/RSCM, Indonesia)
- P126 Consideration of next regimen for advanced endometrial cancer with microsatellite instability
Hyewon Chung (Keimyung University, Korea)
- P127 Comparison of surgical outcomes, 3-year disease free survival rate and overall survival rate between single-port access staging laparoscopy and conventional staging laparoscopy in uterine cancer
Jeel Whan Kim (Yonsei University, Korea)
- P128 Minimally invasive versus abdominal hysterectomy for endometrial carcinoma with glandular or stromal invasion of cervix
Yoo-Young Lee (Samsung Medical Center, Korea)
- P129 Survival outcomes of FIGO stage IIIC and IVB endometrial cancer patients presenting primarily as nodal spreads without peritoneal carcinomatosis
Joo-Hyuk Son (Ajou University, Korea)
- P130 Risk factors for tumor recurrence in surgically managed endometrial cancer: a cohort study
Kathleen Gizelle Alfonso (Society of Gynecologic Oncologists of the Philippines, Philippines)
- P131 Association of abnormal pap smear with occult cervical stromal invasion in patients with endometrial cancer
Kewalin Khumthong (Khon Kaen University, Thailand)
- P132 When everything turns to black - Man: a sign of impending doom;;;; Malignant acanthosis nigricans (MAN) in a patient with endometrial carcinoma
Patricia Tanchuling (Philippine General Hospital, Philippines)
- P133 Association of preoperative serum HE4 levels on survival of patients with endometrial cancer
Putsarat Insin (Rajavithi Hospital, Thailand)
- P134 Successful removal of a peritoneovenous shunt for severe chylous ascites after a para-aortic lymphadenectomy: a case report
Tsutomu Ida (Tokyo Metropolitan Tama Medical Center, Japan)
- P135 Have type 1 and 2 endometrial cancers the different clinicopathological features and survival outcomes?
U Chul Ju (Chonnam National University, Korea)

- P136 Clinicopathological and survival analysis of synchronous primary endometrial and ovarian cancer: a single institution review of 29 cases
U Chul Ju (Chonnam National University, Korea)
- P137 Dual targeting of estrogen receptor α and estrogen-related receptor α : a novel endocrine therapy for endometrial cancer
Xiaodan Mao (Fujian Medical University, China)
- P138 Doubting the prognostic significance of lymphovascular space invasion to endometrioid endometrial cancer patients among Chinese population: a retrospective study of 584 cases from a single center
Yibo Dai (Peking University People's Hospital, China)
- P139 Comparison of outcome between one-step versus two-step sentinel lymph node biopsy in endometrial cancer
Yoo-Na Kim (Yonsei University, Korea)
- P140 Imaging-based definition of lower uterine segment carcinoma to improve the detection sensitivity of probable Lynch syndrome
Yukiharu Todo (Hokkaido Cancer Center, Japan)
-
- Rare Tumors including Uterine Sarcoma & GTD**
- P141 Embryonal rhabdomyosarcoma arising from uterine corpus in a postmenopausal woman : a case report and literature review
A-jaree Senthong (Surin Hospital, Thailand)
- P142 Undifferentiated endometrial sarcoma: an uncommon case report
Baasansuren Nyamkhuu (National Cancer Center, Mongolia)
- P143 Lymphocyte-monocyte ratio predicts uterine sarcoma aggressiveness
Hong Bae Kim (Hallym University, Korea)
- P144 Cytoreductive surgery and HIPEC for primary peritoneal anaplastic ependymoma with extensive peritoneal carcinomatosis
Jin-Hyung Shim (Ajou University, Korea)
- P145 Cytoreductive surgery and HIPEC for intraabdominal synovial sarcoma with peritoneal carcinomatosis
Jin-Hyung Shim (Ajou University, Korea)
- P146 Immunohistochemical staining of PD-L1 and CD8+ T-cells in tumor tissue is a useful predictor of nivolumab efficacy against mucosal melanoma
Kohei Omatsu (Cancer Institute Hospital, Japan)
- P147 A case of squamous cell carcinoma of unknown primary site
Koichiro Lee (Sakai City Medical Center, Japan)
- P148 The accuracy of ultrasound in diagnosing first trimester molar pregnancy
Renne Riza Medalla (Philippine General Hospital, Philippines)
- P149 Giant uterine mass with uterine smooth muscle tumor of uncertain malignant potential: a case report
Tae-Kyu Jang (Keimyung University, Korea)
- P150 Identifying the factors affecting chemotherapy resistance of single agent methotrexate in gestational trophoblast neoplasia (gtn) low-risk stage I, II and III therapy in Hasan Sadikin hospital West Java
Tendi Robby Setia (Hasan Sadikin Hospital, Indonesia)
- P151 Twin pregnancy post external beam radiation therapy (EBRT) in gestational trophoblastic neoplasia (GTN) Invading to right cornu and vaginal metastasis treated with single-agent chemotherapy; all treatments are safe to preserve fertility function
Tricia Dewi Anggraeni (University of Indonesia, Indonesia)
- P152 PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia
Yang Xiang (Peking Union Medical College, China)
- P153 Prediction of distant metastasis in patients with early ~ locally advanced uterine sarcoma
Yeni Kim (University of Ulsan, Korea)
- P154 Management and prognosis of relapsed gestational trophoblastic neoplasia: a 14-year experience
Xuan Zong (Peking Union Medical College, China)
- P155 The challenge in diagnosing endometrial stromal sarcoma
Zhyra Gail Catli (Jose B. Lingad Memorial Regional Hospital, Philippines)
-
- Genetics**
- P156 Downregulation of miR-214-3p in exosomes contributes to fibrosis as determined by primary endometrial cell isolation from patients with endometriosis and by endometrial cell line culture: the role of exosomes in the horizontal transfer of miR-214-3p
Jinwei Miao (Beijing Obstetrics and Gynecology Hospital, Capital Medical University, China)
- P157 Effectiveness of a newly designed genetic panel containing 28 genes for gynecological cancers: an exploratory study
Hodaka Takeuchi (Shinshu University, Japan)

- P158 Reclassification of BRCA1 and BRCA2 variants of uncertain significance in ovarian epithelial, fallopian tube, and primary peritoneal cancer
Hyeong In Ha (National Cancer Center, Korea)
- P159 Nation-wide analysis of clinical NGS panel for performing precision oncology for epithelial ovarian, peritoneal and tubal cancer patient (KGOG 3047 study) ? Preliminary analysis reports of retrospective study
Jihye Kim (Dankook University, Korea)
- P160 Real-world experience of pembrolizumab in patients with gynecologic malignancy: the first reports of Republic of Korea
Myeong Seon Kim (Sungkyunkwan University, Korea)
- P161 Correlation between homeobox gene upregulation and poor survival outcomes in cervical carcinoma
Sung Pil Choo (Yonsei University, Korea)
- P162 Dysregulated expression of homeobox family genes may influence survival outcomes of patients with epithelial ovarian cancer: analysis of data from the cancer genome atlas
Sung Pil Choo (Yonsei University, Korea)

Quality of Life

- P163 Are we ready for the increasing burden of cancer care cost? A willing-to-pay analysis
Hyemin Yeo (National Cancer Center, Korea)
- P164 Conditional relative survival of cervical cancer: analysis of Korean central cancer registry data
Jaeman Bae (Hanyang University, Korea)
- P165 Sexual dysfunction, symptomatic lymphedema and impaired global QOL are common in ovarian cancer survivors
Jooyoung Kim (Seoul National University, Korea)
- P166 Short-term benefits of balneotherapy for patients with chronic pelvic pain: a pilot study in Korea
Kyung-Jin Min (Korea University, Korea)
- P167 Sexual function in cervical cancer survivors: a multi-level meta-analysis with qualitative comparative analysis
Nutthaporn Chandeying (Navamindradhiraj University, Thailand)
- P168 A longitudinal study of symptom experience in Ramathibodi Hospital cervical cancer patients receive chemotherapy: cisplatin
Rachadapan Chaitosa (Ramathibodi Hospital, Thailand)

- P169 Side effects among patients with invasive cervical cancer receiving cisplatin by age range: prospective study
Rachadapan Chaitosa (Ramathibodi Hospital, Thailand)
- P170 Periumbilical infiltration of lidocaine with epinephrine vs bupivacaine for postoperative pain reduction in multi-port laparoscopic adnexal surgery
Whan Shin (Yonsei University, Korea)

Supportive Care

- P171 Cambodian gynecological cancer patients who received treatment at Surin province, supportive care system
Ajaree Sethong (Surin Hospital, Thailand)
- P172 Prevention of venous thromboembolism in gynecologic oncology surgery
Chul Kwon Lim (University of Ulsan, Korea)
- P173 Men's awareness of cervical cancer
Hae Won Kim (Seoul National University, Korea)
- P174 Fear of receiving less effective care: a barrier to effective cancer care cost communication
Hyemin Yeo (National Cancer Center, Korea)

Fertility Preservation

- P175 Korean nurses' attitude toward cancer treatment during pregnancy
Hae Won Kim (Seoul National University, Korea)
- P176 Oncologic and reproductive outcomes of ovarian cystectomy as a fertility-sparing treatment for early-stage epithelial ovarian cancer
Kazuhisa Kitami (Nagoya University, Japan)
- P177 Pregnancy outcome after MPA therapy
Masae Yoo (Osaka Medical College, Japan)
- P178 The feasibility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian insufficiency in patient with malignant ovarian germ cell tumors
Min Chul Choi (CHA University, Korea)
- P179 Characteristics and therapeutic effects for progestin-resistant early endometrial cancer and atypical hyperplasia patients receiving fertility-sparing treatment
Shuang Zhou (Obstetrics and Gynecology Hospital of Fudan University, China)

P180 Does fertility-sparing treatment of endometrial cancer or atypical hyperplasia patients affect their offspring on physical and behavioral development?

Yiqin Wang (Peking University People's Hospital, China)

P181 From circulating to pathological biomarkers: a dynamic study of fertility-sparing treatment of endometrial cancer and atypical hyperplasia

Yiqin Wang (Peking University People's Hospital, China)

Translational Research

P182 Efficient tumor clearance by stimulated CD8+ T cell through combination immunotherapies in cervical cancer bearing mouse

Dae Woo Lee (The Catholic University of Korea, Korea)

P183 Blockade of PD-L1 enhances cancer immunotherapy by regulating dendritic cell maturation

Heng-Cheng Hsu (National Taiwan University Hospital Hsin-Chu Branch, Taiwan)

P184 BET bromodomain proteins, BRD3 and BRD4, play a crucial role in ovarian cancer cell survival

Mi-Kyung Kim (Ewha Womans University, Korea)

P185 Anti-cancer effect of PARP inhibitor (olaparib) with DNA-demethylating agents(5-azacytidine) in ovarian cancer

Soo Young Jeong (Samsung Medical Center, Korea)

P186 DDX53 confers the self-renewal and drug-resistance of ovarian cancer stem-like cells

Sung Taek Park (Hallym University, Korea)

P187 Targeting casein kinase 2 disrupts intracellular trafficking of IGF2R and lysosomal homeostasis and induced cell death in cervical cancer

Takashi Takeda (Keio University, National Cancer Center Research Institute, Japan)

P188 Increase paclitaxel sensitivity to better suppress serous epithelial ovarian cancer via ablating androgen receptor/ aryl hydrocarbon receptor-ABCG2 Axis

Yao-Ching Hung (China Medical University Hospital, Taiwan)

P189 Role of inhibition of fibroblast growth factors (FGFs) / fibroblast growth factor receptors (FGFRs) axis in epithelial ovarian cancer

Yoo-Young Lee (Samsung Medical Center, Korea)

P190 The notch signaling change by catecholamine in epithelial ovarian cancer

Younghan Park (Hallym University, Korea)

P191 CKD-602, a topoisomerase I inhibitor, induces apoptosis and cell-cycle arrest and inhibits invasion in murine cervical cancer

Yuyeon Jung (The Catholic University of Korea, Korea)

Clinical trials, Trials in Progress

P192 Mainstreaming genetic counselling for genetic testing of BRCA1 and BRCA2 in ovarian cancer patients in Malaysia (MaGiC Study)

Anuradha Suberamaniam (University of Malaya Medical Centre, Malaysia)

P193 A multicenter phase I/II a study of BVAC-C in patients with multiple metastatic progress or recurrent HPV 16 or 18 positive cervix cancer after fail to standard care

Byoung Gie Kim (Sungkyunkwan University, Korea)

P194 Reduction Of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial

Hee Seung Kim (Seoul National University, Korea)

P195 KEYNOTE-826: a phase 3 randomized trial of chemotherapy with and without pembrolizumab for first-line treatment of advanced cervical cancer

Jae-Weon Kim (Seoul National University, Korea)

P196 A multi-center, double-blind, randomized, placebo-controlled phase III clinical study evaluating niraparib as maintenance therapy in Chinese patients with platinum-sensitive, recurrent ovarian cancer

Jia Zhang (Fudan University Shanghai Cancer Center, China)

P197 An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer:

Jung-Yun Lee (Yonsei University, Korea)

P198 A phase II study of neoadjuvant chemotherapy plus durvalumab (MEDI4736) and tremelimumab in advanced-stage ovarian cancer:

Jung-Yun Lee (Yonsei University, Korea)

P199 Comparative effectiveness of HIPEC following interval debulking surgery in patients with advanced-stage ovarian cancer: KGOG 3042

Jung-Yun Lee (Yonsei University, Korea)

P200 A phase II trial to evaluate the efficacy of bortezomib and pegylated liposomal doxorubicin in patients with BRCA wild type platinum-resistant recurrent ovarian cancer: KGOG 3044, EBLIN

Jung-Yun Lee (Yonsei University, Korea)

- P201 ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Keiichi Fujiwara (Saitama Medical University International Medical Center, Japan)
- P202 A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer
Keiichi Fujiwara (Saitama Medical University International Medical Center, Japan)
- P203 Randomized phase III trial of long-term low-dose metronomic UFT maintenance therapy versus observation after chemoradiation therapy for locally advanced cervical cancer (GOTIC-002)
Keiichi Fujiwara (Saitama Medical University International Medical Center, Japan)
- P204 A randomized phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. A GOTIC-001/JGOG3019/GCIG Study (iPocc Trial)
Shoji Nagao (Hyogo Cancer Center, Japan)
- P205 ENGOT-EN9/LEAP-001: a phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
Soo Yeon Ihm (MSD Korea, Korea)
- P206 Can neoadjuvant pd-1 blockade reduce risk of distant relapse after primary therapy for resectable, advanced gynecologic malignancies?
Ting-Chang Chang (Chang Gung Memorial Hospital at Linkou, Taiwan)
- P210 Clinical application analysis of sentinel lymph node biopsy in cervical cancer
Hongyi Hou (Peking University People's Hospital, China)
- P211 Clinical application analysis of sentinel lymph node pathologic ultrastaging in early stage cervical cancer
Hongyi Hou (Peking University People's Hospital, China)
- P212 Sentinel lymph node mapping using indocyanine green in robotic surgery for the treatment of endometrial cancer and early-staged cervical cancer
Seongmin Kim (Korea University, Korea)
- P213 The silent mentor as a media preservice surgical training in gynecologic oncology fellowship program
Sigit Purbadi (University of Indonesia, Indonesia)

Surgical Techniques

- P207 Single-site vs. multiport robotic staging surgery in endometrial cancer
Athithan Rattanaburi (The Catholic University of Korea, Korea)
- P208 Effectiveness of the bipolar vessel sealer in robot-assisted pelvic and infrarenal paraaortic lymphadenectomy
Do Young Chung (Kyungpook National University, Korea)
- P209 Learning curve analysis and safety of splenectomy of the single gynecologic surgeon
Eun Ji Lee (Seoul National University, Korea)

ONCOLOGY

Living Longer
Living Better



We have +1

PADEXOL Inj.

Anti-Cancer Drug Paclitaxel

천연주목나무추출

Paclitaxel-파덱솔

- _ Natural material
- _ Aceptorol 330
- _ Bio-equivalence
- _ Cost effectiveness

Proven Efficacy & Safety Evidenced by clinical trials¹⁻⁶

Plant Cell Culture Technology
High Quality API* & Injection

1st

국내 1호 Paclitaxel 제제로서
안전성과 유효성 입증



식물세포배양법을 이용한
고순도 Paclitaxel 원료 사용

EU GMP 승인
항암제 전용 시설에서 생산



Proven Efficacy & Safety Evidenced by clinical trials¹⁻⁶

Plant Cell Culture Technology
High Quality API* & Injection

1st

국내 1호 Paclitaxel 제제로서
안전성과 유효성 입증



식물세포배양법을 이용한
고순도 Paclitaxel 원료 사용

EU GMP 승인
항암제 전용 시설에서 생산



References

1. Cancer Research and Treatment 2001;33(6):451-457 A Phase II study of Genexol (paclitaxel) in Metastatic Breast Cancer
2. Cancer Research and Treatment 2003;35(1):30-34 Phase II Clinical Trial of Genexol (paclitaxel) and Cisplatin for Patients with Non-small Cell Lung Cancer
3. Oncology Report 12:2004: 1059-1064 A Multi-Center, Inte Phase II Clinical Trial of Genexol (paclitaxel) and Cisplatin for Patients with advanced gastric Cancer
4. J Clin Oncol, 2013 May 10;31(14):1732-9 A Phase III, Multi-Center, Randomized Trial of Maintenance Versus Observation After Achieving Clinical Response in Patients With Metastatic or Recurrent Breast Cancer Who Received 6 Cycles of Gemcitabine Plus Paclitaxel (GP) as First-Line Chemotherapy
5. Cancer Chemother Pharmacol. 2015 Jun;75(6):1175-82 A Phase III Trial of Second-Line Chemotherapy with Paclitaxel and Irinotecan in Fluoropyrimidine- and Platinum-Pretreated Advanced Gastric Cancer
6. J Clin Oncol 28:15s, 2010 (suppl. abstr 685) Phase Ib/III Study of Primary Chemotherapy with Paclitaxel, Gemcitabine, and Sunitinib in Patients with HER2-negative Stage IIIB Breast Cancer

* Active Pharmaceutical Ingredients

References

1. Cancer Research and Treatment 2001;33(6):451-457 A Phase II study of Genexol (paclitaxel) in Metastatic Breast Cancer
2. Cancer Research and Treatment 2003;35(1):30-34 Phase II Clinical Trial of Genexol (paclitaxel) and Cisplatin for Patients with Non-small Cell Lung Cancer
3. Oncology Report 12:2004: 1059-1064 A Multi-Center, Inte Phase II Clinical Trial of Genexol (paclitaxel) and Cisplatin for Patients with advanced gastric Cancer
4. J Clin Oncol, 2013 May 10;31(14):1732-9 A Phase III, Multi-Center, Randomized Trial of Maintenance Versus Observation After Achieving Clinical Response in Patients With Metastatic or Recurrent Breast Cancer Who Received 6 Cycles of Gemcitabine Plus Paclitaxel (GP) as First-Line Chemotherapy
5. Cancer Chemother Pharmacol. 2015 Jun;75(6):1175-82 A Phase III Trial of Second-Line Chemotherapy with Paclitaxel and Irinotecan in Fluoropyrimidine- and Platinum-Pretreated Advanced Gastric Cancer
6. J Clin Oncol 28:15s, 2010 (suppl. abstr 685) Phase Ib/III Study of Primary Chemotherapy with Paclitaxel, Gemcitabine, and Sunitinib in Patients with HER2-negative Stage IIIB Breast Cancer

* Active Pharmaceutical Ingredients

Tour Information

Tour Information

Songdo International City

It is the center city of the Free Economic Zone of Incheon and 15 international organizations. As you can expect, the cityscape is modern and beautiful. The eye-catching architecture has created a sophisticated urban sensibility. It looks like the nation's stop-level green spaces and parks put bright colors over the city.

* Travel Point : City tour finding metropolitan sense that you imagined

Shopping & Food

One of the pleasures of sightseeing in Songdo International City is shopping. Large shopping malls such as Hyundai Premium Outlets, Triple Street, and NC Cube Canal Walk are popular shopping.

Hyundai Premium Outlets & Triple Street



How to get there

- Bus No. 6, 9, 523-1, 92
- Incheon Subway Line 1, Techno Park Station

NC Cube Canal Walk



How to get there

- Bus No. 82, 6-1

ASGO2019


Check the latest information on
ASGO 2019 Mobile APP!!



ASGO 2019



- Overview of sessions, speakers and exhibitors
- Browse abstracts and presentation files
- Create your personal schedule for the event, including bookmarking the sessions you are interested in



Exhibition

Exhibition is opened at Grand Ballroom C, Lobby (2F) from Thursday, October 10 to Saturday, October 12.

Opening Hours

Thursday, October 10	09:00 – 18:00
Friday, October 11	09:00 – 18:00
Saturday, October 12	09:00 – 18:00

Exhibitors

DIAMOND



SEMI DIAMOND



PLATINUM



GOLD



SILVER



BRONZE



SEMI BRONZE



ADVERTISEMENT




Exhibition Area



No.	Category	Company
D1	Diamond	Roche Korea
D2		Astrazeneca
SD1	Semi-Diamond	Takeda Pharmaceuticals Korea
P1	Platinum	MSD
G1	Gold	Shinpoong Pharm
G2		Intuitive
G3		Boryung Pharme
G4		SAMYANG
G5		Roche Diagnostics Korea
S1	Silver	Dalimbiotech
S2		CJ Healthcare
S3		JW PHARMACEUTICAL
S4		Johnson & Johnson Medical
S5		Bayer Korea
S6		Hanmi Pharm
S7		ckd pharm
B1	Bronze	Hanmihealthcare
B2		Janssen
B3		KARL STORZ ENDOSCOPY KOREA CO.,LTD
B4		Pfizer Korea
B5		baxter
B6		OLYMPUS KOREA
B7		Bard Korea
B8		DW Pharm
B9		GSK
B10		Pharmbio
B11		Medifine
B12		Queen-Spec
B13		Kyowa Kirin Korea
B14		Stryker Korea
SB1	Semi-Bronze	GA YOUNG MEDICAL
SB2		Yungjin pharmaceutical
SB3		DONGA-ST
SB4		MEDEN
SB5		SAMSUNG
SB6		Uniens
SB7		Philosys healthcare
SB8		abnobaKOREA
SB9		Menarini
SB10		HAN KOOK PHARMED CO., LTD
SB11		Teva-handok
SB12		Cardinal Health
SB13		SEJONG MEDICAL
SB14		Medtronic
SB15		MEDITECH INFRAMED
46	ASGO	JGO
47		TGCS

Floor Plan



Thursday, October 10

GBR A, B

Special Symposium 1
Plenary Session 1

GBR A

Welcome Reception

GBR B

Symposium 1
Symposium 2

Room 204, 205

Shingo Fujii Medical Academy
Education Session 1
Education Session 2

Room 206, 207

Oral 1
Oral 2

Friday, October 11

GBR A, B

Plenary Session 2
Special Symposium 2
Plenary Session 3

GBR A

Symposium 3
Symposium 5
Education Session 4

GBR B

Symposium 4
Symposium 6
Special Session 2

Room 205

Ovarian Cancer Roundtable
Session of Chinese Gynecologic Oncologists

Room 206, 207

Education Session 3
Special Session 1
Oral 3
Oral 4

PBR A, B

Banquet

Saturday, October 12

GBR A

Special Session 3
Special Session 4
Education Session 6
Special Symposium 3
Symposium 7
Symposium 8

Room 204, 205

Poster Discussion
Education Session 5
Film 1A
Film 1B
Education Session 7
Education Session 8

Room 206, 207

Oral 5
Oral 6
Special Session 5
Oral 7



The 7th Biennial Meeting of
Asian Society of Gynecologic Oncology

25-27 November 2021

Venue : Shangri-La Hotel Bangkok